Helius Medical Q4 revenue down 52% YoY; net loss per share $1.47 vs $8.66

Solana Co

Q4 2023 revenue $134K, down from $282K in Q4 2022, due to US PTAP expiration and lower Canada sales.
Net loss $1.0M in Q4 2023 vs $4.9M in Q4 2022; basic EPS loss $1.47 vs $8.66.
FY2023 revenue $644K vs $787K; net loss $8.9M vs $14.1M; operating loss $12.4M vs $15.5M.
Cash $5.2M at Dec 31, 2023; raised $1.3M in Q1 2024 ATM at avg $9.27/share, runway to Q3 2024.
CMS assigned HCPCS codes for PoNS mouthpiece/controller effective Apr 1, 2024; targeting Medicare reimbursement by Oct 1, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Solana Co reported financial results for the quarter and full year ended December 31, 2023.

Period: the quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, Helius Medical Technologies, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Solana Co filing history →

Source: SEC EDGAR

accession 0001558370-24-004251

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.